Definitions of 'Cure' After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?

Autor: Andreas Boehle, MD, PhD, Dorothea Zywietz, Irina Robrahn-Nitschke, MD, Inke R. Koenig, MD, PhD, Achim Lusch, MD, PhD

Publikováno v: Advances in Radiation Oncology, Vol 8, Iss 2, Pp 101112- (2023)

Purpose: The aim of this study was to compare a surgical with a Phoenix-derived definition of cure at 4 years after treatment by 125J low-dose-rate brachytherapy (LDR-BT) in patients with low- and intermediate-risk prostate cancer. Methods and Materi

Externí odkaz: https://doaj.org/article/f5d9e1cb0f48414da21111f21e248ae6

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG

Autor: Mark S. Soloway, Donald L. Lamm, Ashish M. Kamat, Debasish Sundi, Andreas Boehle, J. Alfred Witjes, Maurizio Brausi, Joan Palou, Roger Buckley, Raj Persad, Marc Colombel

Publikováno v: Nature Reviews. Urology, 14, 4, pp. 244-255
Nature Reviews. Urology, 14, 244-255

Item does not contain fulltext Intravesical immunotherapy with live attenuated BCG remains the standard of care for patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Most patients initially respond, but recurre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15e1165429f9e47aaa2bf0d8a7bb4d48
https://doi.org/10.1038/nrurol.2017.16

European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update

Autor: Joan Palou, Willem Oosterlinck, Marko Babjuk, Richard Sylvester, E. Kaasinen, Richard Zigeuner, Andreas Boehle, Morgan Rouprêt

Publikováno v: EUROPEAN UROLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Actas Urologicas Espanolas

Context: The European Association of Urology (EAU) Guideline Group for urothelial cell carcinoma of the upper urinary tract (UUT-UCC) has prepared new guidelines to aid clinicians in assessing the current evidence-based management of UUT-UCC and to i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b6c76a83414e192bb77dc130e8dfaa3
https://doi.org/10.1016/j.acuroe.2011.09.001

BCG-Therapie des oberflächlichen Harnblasenkarzinoms : Bestandsaufnahme aus Klinik und Praxis

Autor: Andreas Böhle, Dieter Jocham

In diesem Buch werden zahlreiche Aspekte zur intravesikalen Therapie des oberflächlichen Harnblasenkarzinoms mit Bacillus Calmette-Guérin (BCG) erörtert. Um den Einstieg in die Thematik zu erleichtern, befaßt sich zunächst ein kurzer Überblick

Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987

Autor: Sandrine Marreaud, Eric Winquist, Joaquim Bellmunt, Sandra Collette, Hans von der Maase, Richard Sylvester, Graham M. Mead, Gedske Daugaard, Andreas Boehle, Leslie R. Laufman, Derek Raghavan, Luis Paz-Ares, Ronald de Wit, Maria De Santis, Iwona Skoneczna, Christine Chevreau

Publikováno v: Journal of Clinical Oncology, 30(10), 1107-1113. American Society of Clinical Oncology

Purpose The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that a three-drug regimen that included paclitaxel had greater antitumor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a5698d00924801a628c4a7b5d3b4254
https://europepmc.org/articles/PMC3341152/